Three members of HAPLO-iPS COST Action CA21151 are editors of a special issue of Frontiers in Immunology with topic “The Significance of Induced Pluripotent Stem Cells in Translational Medicine”.
Helen Latsoudis (Foundation for Research and Technology Hellas (FORTH), Heraklion, Greece), Julia Skokowa (University of Tübingen, Germany) and Belen Alvarez-Palomo – Banc de Sang i Teixits, Barcelona, Spain) are welcoming manuscripts focusing but not limited to the following sub-topics:
- Modeling human diseases using IPS-derived cellular models (e.g. co-cultures, organoids);
- IPSC-based drug screening and development or repurposing;
- Clinical trials using iPS-derived cellular products;
- Optimization protocols for the efficient and efficacious use of iPS-derived cells;
- Framework profiling the design, quality control, clinical testing and regulatory validity of iPSCs use;
- Strategies to reduce graft-versus-host disease using allogeneic iPS-derived cellular products;
Potential measures to overcome hurdles in iPSC-based therapy safety, efficiency and logistics, e.g.:
- Propensity for teratoma formation
- Genomic stability
- Limited therapeutic response
- Reproducibility
- Manufacturing process
This Research Topic accepts Original Research, Systematic Review, Methods, Review and Mini-Review, Hypothesis & Theory, Clinical Trial, Classification, Technology and Code, Study Protocol, Perspective, Case Report, Conceptual Analysis, Brief Research Report, Data Report, General Commentary.
More information about this issue and all the details related to the submission process can be found at: https://www.frontiersin.org/research-topics/69425/the-significance-of-induced-pluripotent-stem-cells-in-translational-medicine
